TrialLeukemia & lymphoma2013

The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).

Sonali M Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.